Clinical Trials on Recurrent NSCLC in Ireland

Total 253 results

St Patrick's Hospital, Ireland

Terminated

Ketamine for Relapse Prevention in Recurrent Depressive Disorder (KINDRED)

Depression | Major Depressive Disorder | Relapse | Recurrent Depressive Disorder

Ireland
Kiniksa Pharmaceuticals (UK), Ltd.

Completed

A Pilot Study of KPL-914 in Recurrent Pericarditis

Recurrent Pericarditis

United States
Cancer Trials Ireland
University College Dublin; Technological University Dublin

Recruiting

'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung) (SOURCE Lung)

NSCLC/Oligometastatic Cancer (Single Lung Lesion)

Ireland
University College Dublin
Mater Misericordiae University Hospital; Irish Cancer Society

Recruiting

COMpassion FOcused Therapy and Breathing Pattern REtraining After Cancer Recurrence (COMFORT)

Psychological Distress | Cancer Recurrence

Ireland
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
AstraZeneca

Completed

Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study

NSCLC

Sweden, Bulgaria, Mexico, Russian Federation, Turkey, United Kingdom, Philippines, Malaysia, Germany, Hungary, Latvia, Lithuania, Poland, Romania, Netherlands, Norway, Argentina, Australia, Canada, Slovakia, Greece, Taiwan, Thailand, ... and more
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma

United States
University of Colorado, Denver
Boston Scientific Corporation

Terminated

Salvage Cryotherapy in Recurrent Prostate Cancer (SCORE)

Recurrent Prostate Cancer

United States
ETOP IBCSG Partners Foundation
Mirati Therapeutics Inc.

Recruiting

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status (ADEPPT)

NSCLC Stage IV | KRAS P.G12C

Ireland, Italy, France, Spain, United Kingdom, Belgium
Cancer Trials Ireland

Recruiting

Breast Cancer Proteomics and Molecular Heterogeneity

Primary Breast Cancer | Recurrent/Metastatic Breast Cancer

Ireland
National Cancer Institute (NCI)
NRG Oncology

Withdrawn

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditions

United States
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Nutricia Research

Recruiting

Effect of an Oral Nutritional Supplement on Muscle Mass During Anticancer Treatment (ALLIES)

Non-small Cell Lung Cancer (NSCLC) | Colorectal Cancer (CRC)

Ireland
Oblato, Inc.

Active, not recruiting

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

Recurrent Malignant Glioma | Brain Glioblastoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
St Vincent's University Hospital, Ireland
PelvEx collaborative

Not yet recruiting

PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting

Locally Advanced Rectal Cancer | Recurrent Rectal Cancer | Multidisciplinary Communication | Multidisciplinary Team Meeting (MDT) | Treatment Decisions

Ireland
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Recurrent Uterine Corpus Sarcoma | Uterine Corpus Leiomyosarcoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Ovarian Epithelial Tumor

United States
National University of Ireland, Galway, Ireland

Recruiting

Fat Grafting in Reducing Recurrence in Patients With Healed Venous Ulcers A Prospective Randomised Clinical Pilot Study

Varicose Ulcer

Ireland
Spexis AG

Terminated

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (FORTRESS)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

Spain, Belgium, United States, United Kingdom, Korea, Republic of, Taiwan, Italy, Russian Federation, Czechia, France, Brazil, Argentina, Ukraine
Cancer Trials Ireland

Completed

Circulating miRNAs.

Breast Cancer | Recurrent Breast Cancer | Newly Diagnosed Breast Cancer

Ireland
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Gliosarcoma | Recurrent Glioblastoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy

Recurrent Uterine Corpus Sarcoma | Uterine Corpus Leiomyosarcoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Malignant Ovarian Clear Cell Tumor

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Terminated

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Recurrent Uterine Corpus Sarcoma | Uterine Carcinosarcoma

United States
St. James's Hospital, Ireland
Karolinska Institutet; St Mary's Hospital, Paddington, London

Completed

European iNvestigation of SUrveillance After Resection for Esophageal Cancer (ENSURE)

Esophageal Cancer | Chemoradiation | Chemotherapy | Surgery | Metastatic Cancer | Radiation | Recurrent Esophageal Cancer

Sweden, Ireland, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Non-Hodgkin Lymphoma

United States, Canada, Puerto Rico, Australia, Switzerland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Agenus Inc.

Terminated

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Gliosarcoma | Recurrent Glioblastoma | Recurrent Adult Brain Tumor

United States
Jun Zhang, MD, PhD
Rhode Island Hospital

Recruiting

Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients (Microdurva)

NSCLC, Stage III | Locally Advanced Lung Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma

United States, Puerto Rico
Aadi Bioscience, Inc.

Recruiting

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Cancer | Endometrial Cancer | Tumor | Recurrent Endometrial Carcinoma | Endometrioid Endometrial Cancer | Endometrioid Tumor

United States
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
NanoBio Corporation

Completed

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)

Recurrent Herpes Simplex Labialis

United States
NanoBio Corporation

Completed

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS) (SHaRCS)

Recurrent Herpes Labialis

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Endometrial Carcinoma

United States
Adnexus, A Bristol-Myers Squibb R&D Company

Unknown

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Brain and Central Nervous System Tumors | Recurrent Glioblastoma Multiforme

United States

Clinical Trials on Recurrent NSCLC in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations